Polymorph Stability for CNS Drug Handling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug formulations face challenges in achieving stable, chemically pure, and reproducible plasma concentration profiles, with issues related to chemical and solid-state stability, handling, and storage of active ingredients, particularly for compounds like (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine p-hydroxybenzoate used in treating central nervous system disorders.
Innovation Solution
Development of two polymorphic forms (Polymorphs A and B) of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine p-hydroxybenzoate, which are stable, crystalline, and can be stored effectively, along with methods for their preparation and incorporation into pharmaceutical compositions for enhanced therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If a stable crystalline form of the drug is obtained, then ease of handling, ease of preparation of pharmaceutical compositions, and solubility profile are improved, but the complexity of obtaining and characterizing multiple polymorph forms increases
Solution Approach 1:
The patent applies parameter changes by identifying and characterizing different polymorphic forms (Form A and Form B) of the compound, each with distinct crystal structures and physical properties. By establishing specific characterization parameters (XRD patterns, DSC curves, solubility profiles) for each polymorph, the patent enables selective preparation and consistent quality control, thereby improving ease of handling while managing the complexity through systematic parameter definition.
2Stability of the object's composition
If multiple polymorph forms are developed, then chemical and solid-state stability are improved, but the manufacturing process complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-characterizing the stability properties of different polymorph forms under various storage conditions before commercial manufacturing. By establishing baseline stability data, storage requirements, and transformation conditions for each polymorph in advance, the patent enables manufacturers to select the most stable form and implement appropriate storage and handling protocols, thereby improving stability while managing manufacturing complexity through advance preparation.
3Duration of action of stationary object
If polymorphic forms with prolonged storage capability are created, then shelf life is improved, but the difficulty of maintaining consistent physico-chemical characteristics during storage increases
Solution Approach 1:
The patent applies feedback by establishing comprehensive characterization methods and quality control parameters for each polymorph form that can be used to monitor and verify consistency during storage. By defining specific XRD patterns, DSC profiles, and solubility ranges as acceptance criteria, the patent enables continuous verification of physico-chemical characteristics throughout the shelf life, thereby extending storage duration while maintaining precision through systematic feedback monitoring.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymorphic forms provide a stable and effective treatment for various central nervous system disorders by maintaining chemical and solid-state stability, ensuring prolonged storage and improved handling, while interacting effectively with nicotinic receptor sites to modulate neurotransmitter release and treat conditions like Alzheimer's disease, Parkinson's, and other CNS-related issues.
Implementation Method 1
The present invention relates to two polymorphic forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine p-hydroxybenzoate... Polymorphs A and B of the p-hydroxybenzoate salt... which are stable, crystalline, and can be stored effectively
Data Source
AI summary
Polymorph forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine p-hydroxybenzoate, and methods for their preparation, pharmaceutical composition containing said polymorph(s) and use, are disclosed. The polymorphs can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders.